CMPX Compass Therapeutics
Compass Therapeutics earnings company data as of 4:45 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 4 Nov | EPS | -0.13 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by CMPX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $97K bought by 2 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Neil Lerner Chief Accounting OfficerBuy$18K 20,000 shares at $0.9200 +5% to stakeTraded Oct 1 Filed Oct 2
-
Neil Lerner Chief Accounting OfficerBuy$2,850 2,500 shares at $1.14 +0.6% to stakeTraded Sep 24 Filed Sep 25
-
Neil Lerner Chief Accounting OfficerBuy$28K 15,000 shares at $1.89 +3.9% to stakeTraded Apr 29 Filed Apr 30
-
Jonathan Anderman General CounselBuy$47K 25,000 shares at $1.89 +15% to stakeTraded Apr 29 Filed Apr 30
Also filed in the last 12 months, not counted as buying or selling: 6 stock grants and 3 share withholdings for taxes.
SEC filings
Recent issuer filings from EDGAR, 19 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 7.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | FORM 10-Q | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 5.03,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | FORM 10-Q | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | FORM 10-K | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,8.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.